Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
07/17/2002
Trade Name:
Nasonex-nasal Elocon - topical
Generic Name or Proper Name (*):
mometasone
Indications Studied:
Nasonex - Perennial and seasonal allergic rhinitis Elocon - Relief of inflammatory and pruritic manifestations of corticosteroid dermatose
Label Changes Summary:
Nasonex Nasal Spray Extended age range from 3 years down to 2 years In a clinical study in which pediatric patients 2-5 years were treated with mometasone nasal spray for up to 42 consecutive days, no significant effect on adrenal function was found Upper respiratory tract infection was more common with Nasonex (2/28) compared to placebo (0/28) Elocon Cream & Ointment Evidence of HPA axis suppression in pediatric patients 6-23 months of age Outlined local AE's as well as skin atrophy in pediatric patients 6-23 months of age Approved down to 2 years of age as in previous labeling Elocon Lotion Safety and effectiveness have not been established in pediatric patients below 12 years of age and use <12 year old is not recommended Should not be used for the treatment of diaper dermatitis
Product Labeling:
Labeling
BPCA(B):
B
Sponsor:
Schering
Pediatric Exclusivity Granted Date:
11/07/2001
NNPS:
FALSE'
Therapeutic Category:
Anti-inflammatory, topical
-
-